Press Release: Novartis highlights scientific -2-

-------------------------- ------------------------------------------------------------------ ----------------------

Kymriah(R) Real-world outcomes for patients with relapsed or Abstract #656

(tisagenlecleucel) refractory (r/r) aggressive B-cell non-Hodgkin's lymphoma Oral Presentation

(aBNHL) treated with commercial tisagenlecleucel: Sunday, December 11

subgroup analyses from the Center for International 4:45 PM ET

Blood and Marrow Transplant Research (CIBMTR) Registry

-------------------------- ------------------------------------------------------------------ ----------------------

YTB323 YTB323 (rapcabtagene autoleucel) demonstrates durable Abstract #439

(rapcabtagene autoleucel) efficacy and a manageable safety profile in patients Oral Presentation

with relapsed/refractory diffuse large B-cell lymphoma Sunday, December 11

(r/r DLBCL): Phase I study update 9:30 AM ET

-------------------------- ------------------------------------------------------------------ ----------------------

Jakavi(R) (ruxolitinib) Ruxolitinib in pediatric patients with treatment-naive Abstract #572

or steroid refractory acute graft versus host disease: Oral Presentation

Primary findings from the Phase I/II REACH4 study Sunday, December 11

12:15 PM ET

-------------------------- ------------------------------------------------------------------ ----------------------

Sabatolimab Primary results of STIMULUS-MDS1: A randomized, double-blind, Abstract #853

(MBG453) placebo-controlled Phase II study of TIM-3 inhibition Oral Presentation

with sabatolimab added to hypomethylating agents (hmas) Monday, December 12

in adult patients with higher-risk myelodysplastic 2:45 PM ET

syndromes (MDS)

-------------------------- ------------------------------------------------------------------ ----------------------

Sabatolimab Disease characteristics and International Prognostic Abstract #559

(MBG453) Scoring Systems (IPSS, IPSS-R, IPSS-M) in adult patients Oral Presentation

with higher-risk myelodysplastic syndromes (MDS) participating Sunday, December 11

in two randomized, double-blind, placebo-controlled 12:00 PM ET

studies with intravenous sabatolimab

added to hypomethylating agents (HMA) (STIMULUS-MDS1

and MDS2)

-------------------------- ------------------------------------------------------------------ ----------------------

Product Information

Approved indications for products vary by country and not all indications are available in every country. The product safety and efficacy profiles have not yet been established outside the approved indications. Because of the uncertainty of clinical trials, there is no guarantee that compounds will become commercially available with additional indications.

For full prescribing information, including approved indications and important safety information about marketed products, please visit https://www.novartisoncology.com/news/product-portfolio.

Disclaimer

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "seek," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis is reimagining medicine to improve and extend people's lives. We deliver high-value medicines that alleviate society's greatest disease burdens through technology leadership in R&D and novel access approaches. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. About 108,000 people of more than 140 nationalities work together to bring Novartis products to nearly 800 million people around the world. Find out more at https://www.novartis.com

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews https://twitter.com/novartisnews

For Novartis multimedia content, please visit https://www.novartis.com/news/media-library

For questions about the site or required registration, please contact media.relations@novartis.com

# # #

* Kisqali was developed by the Novartis Institutes for BioMedical Research (NIBR) under a research collaboration with Astex Pharmaceuticals.

Investigator-initiated trial.

Novartis Media Relations

E-mail: media.relations@novartis.com

Central North America

Richard Jarvis +41 79 584 2326 Julie Masow +1 862 579 8456

Anja von Treskow +41 79 392 9697 Michael Meo +1 862 274 5414

Mary

Anna Schäfers +41 79 801 7267 Carmichael +1 862 200 8344

Switzerland

Satoshi Sugimoto +41 79 619 2035

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Sloan Simpson +1 862 345 4440

Nicole Zinsli-Somm +41 61 324 3809 Parag Mahanti +1 973 876 4912

Isabella Zinck +41 61 324 7188

(END) Dow Jones Newswires

November 22, 2022 09:25 ET (14:25 GMT)